Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895955 | 0.89 | PTPN1 (0.38) | KDM4ELMNAALDH1A1PTPN1APP | |
| SCHEMBL23540421 | 0.84 | PTPN1 (0.46) | KDM4ELMNAAKR1C3ALDH1A1PKM | |
| SCHEMBL30026978 | 0.84 | PTPN1 (0.46) | KDM4ELMNAAKR1C3ALDH1A1PKM | |
| SCHEMBL3919344 | 0.84 | KDM4E (0.53) | KDM4ELMNAAKR1C3ALDH1A1PKM | |
| SCHEMBL3919349 | 0.84 | KDM4E (0.53) | KDM4ELMNAAKR1C3ALDH1A1PKM | |
| SCHEMBL2896992 | 0.81 | PTPN1 (0.43) | PTPN1 | |
| SCHEMBL2895984 | 0.81 | PTPN1 (0.45) | PTPN1 | |
| SCHEMBL2895402 | 0.81 | KDM1A (0.46) | PTGER1PTPN1 | |
| SCHEMBL2889394 | 0.81 | APP (0.40) | KDM4EALDH1A1APPHPGD | |
| SCHEMBL2895219 | 0.81 | PTPN1 (0.43) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | KDM4E 2879/4885LMNA 4853/4885AKR1C3 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.